AYTU BIOPHARMA, INC
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
AYTU$1.79-2.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Consolidated Statements of Operations
(in thousands, except share and per share data)
| Three Months Ended · Nine Months Ended | ||||
|---|---|---|---|---|
| March 31, | March 31, | |||
| 2025 | 2024 | 2025 | 2024 | |
| Net revenue | $18,452 | $14,025 | $51,247 | $50,590 |
| Cost of sales | 5,646 | 3,664 | 15,670 | 12,588 |
| Gross profit | 12,806 | 10,361 | 35,577 | 38,002 |
| Operating expenses: | ||||
| Selling and marketing | 5,194 | 5,352 | 16,125 | 16,661 |
| General and administrative | 4,109 | 4,831 | 13,683 | 15,926 |
| Research and development | 162 | 611 | 1,110 | 1,727 |
| Amortization of intangible assets | 920 | 920 | 2,762 | 2,762 |
| Restructuring costs | — | 244 | 2,101 | 244 |
| Total operating expenses | 10,385 | 11,958 | 35,781 | 37,320 |
| Income (loss) from operations | 2,421 | (1,597) | (204) | 682 |
| Other income, net | 36 | 70 | 718 | 750 |
| Interest expense | (900) | (1,257) | (2,973) | (3,806) |
| Derivative warrant liabilities gain (loss) | 2,261 | 1,017 | 8,157 | (5,467) |
| Income (loss) from continuing operations before income tax expense | 3,818 | (1,767) | 5,698 | (7,841) |
| Income tax benefit (expense) | 122 | (521) | — | (1,301) |
| Net income (loss) from continuing operations | 3,940 | (2,288) | 5,698 | (9,142) |
| Net income (loss) from discontinued operations, net of tax | 54 | (599) | 558 | (2,085) |
| Net income (loss) | $3,994 | $(2,887) | $6,256 | $(11,227) |
| Basic weighted-average common shares outstanding (note 17) | 6,134,634 | 5,533,555 | 6,111,550 | 5,511,089 |
| Diluted weighted-average common shares outstanding (note 17) | 8,204,453 | 5,533,555 | 8,606,013 | 5,511,089 |
| Net income (loss) per share (note 17): | ||||
| Basic - continuing operations | $0.64 | $(0.41) | $0.93 | $(1.66) |
| Diluted - continuing operations | $0.20 | $(0.41) | $(0.29) | $(1.66) |
| Basic - discontinued operations, net of tax | $0.01 | $(0.11) | $0.09 | $(0.38) |
| Diluted - discontinued operations, net of tax | $0.01 | $(0.11) | $0.06 | $(0.38) |
| Basic - net income (loss) | $0.65 | $(0.52) | $1.02 | $(2.04) |
| Diluted - net income (loss) | $0.21 | $(0.52) | $(0.22) | $(2.04) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.